Cholesterol guidelines setback

Share this article:

Last week's news that new cholesterol guidelines were in place revved up industry chatter about what this could mean for the statin market. Yet a problem has surfaced: the calculator that would help doctors calculate patient risk is not working right.

The New York Times reports that the calculator “could mistakenly suggest that millions more people are candidates for statin drugs.” The NYT says the American Heart Association and American College of Cardiology are saying that although the calculator is not running as expected, the tool is a sign of progress.

The two groups developed the new guidelines which focus less on cholesterol levels and more on heart disease/stroke risk if a patient has already made lifestyle changes (read: diet and exercise). The risks, as noted by CNN, include factors such as whether a patient is diabetic, and/or has heart disease. The NYT notes that target levels will still be important for patients with high LDL levels.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Business Briefs

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Business Briefs

Novartis said to be stepping out of HCV

Novartis is said to have relinquished rights to an investigational hep. C treatment, signaling its exit from the therapeutic space, according to a former partner's announcement.

Monday Moves: September 15

Hires and promotions for manufacturers, regulatory and agencies

Kantar acquires Evidências, expands Brazilian presence

The company's acquisition signals the growing importance of understanding the Brazilian healthcare market and evidence-based healthcare management services.